A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Indiana University
Study ID
NCT00369889
Phase
PHASE2
Status
Completed

Conditions

  • Thymic Cancer
  • Thymoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine the rate of response with the combination of erlotinib and bevacizumab in previously treated patients with thymoma or thymic carcinoma, and to determine potential molecular markers that may predict response to therapy in patients with thymoma or thymic carcinoma.

Key Dates

First listed
Aug 30, 2006
Start date
Aug 31, 2006
Status verified
May 2014
Primary completion
Sep 30, 2007
Completion
Sep 30, 2007

Study Design

Enrollment
18 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To determine the objective response rate of the combination of erlotinib and bevacizumab in using RECIST. [ Time Frame: completion of study ]

Locations (1)

FacilityCityStateZIPSite coordinators
Indiana University Cancer CenterIndianapolisIndiana46202-

Find similar trials in Indianapolis, IN

By research site
Indiana University Cancer Center· Indianapolis, IN

Related Studies